In summary, this study revealed that SPP1 is a poor prognostic indicator for GC patients, and that the SPP1–CD44 axis mediating the interplay between SPP1+ macrophages and cancer cells may be a potential therapeutic target for GC. This evidence concerns the gene CD44 and cancer.